KR20130083798A - Composition for improving skin wrinkle and whitening - Google Patents
Composition for improving skin wrinkle and whitening Download PDFInfo
- Publication number
- KR20130083798A KR20130083798A KR1020120047640A KR20120047640A KR20130083798A KR 20130083798 A KR20130083798 A KR 20130083798A KR 1020120047640 A KR1020120047640 A KR 1020120047640A KR 20120047640 A KR20120047640 A KR 20120047640A KR 20130083798 A KR20130083798 A KR 20130083798A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- active ingredient
- skin
- composition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000037303 wrinkles Effects 0.000 title claims abstract description 51
- 230000002087 whitening effect Effects 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 239000004480 active ingredient Substances 0.000 claims abstract description 51
- 239000002537 cosmetic Substances 0.000 claims abstract description 29
- 235000013402 health food Nutrition 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- -1 patch Substances 0.000 claims description 14
- 239000006210 lotion Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 5
- 239000000686 essence Substances 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 28
- 108010035532 Collagen Proteins 0.000 abstract description 25
- 102000008186 Collagen Human genes 0.000 abstract description 25
- 229920001436 collagen Polymers 0.000 abstract description 25
- 230000015572 biosynthetic process Effects 0.000 abstract description 16
- HPWWQPXTUDMRBI-NJPMDSMTSA-N monotropein Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@](O)(CO)C=C[C@@H]2C(C(O)=O)=CO1 HPWWQPXTUDMRBI-NJPMDSMTSA-N 0.000 abstract description 16
- 238000003786 synthesis reaction Methods 0.000 abstract description 16
- HPWWQPXTUDMRBI-UHFFFAOYSA-N (4aS)-1c-beta-D-Glucopyranosyloxy-7t-hydroxy-7c-hydroxymethyl-(4ar,7ac)-1,4a,7,7a-tetrahydro-cyclopenta[c]pyran-4-carbonsaeure Natural products OC1C(O)C(O)C(CO)OC1OC1C2C(O)(CO)C=CC2C(C(O)=O)=CO1 HPWWQPXTUDMRBI-UHFFFAOYSA-N 0.000 abstract description 13
- HPWWQPXTUDMRBI-COZRGLNQSA-N Monotropein Natural products O=C(O)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(CO)C=C2 HPWWQPXTUDMRBI-COZRGLNQSA-N 0.000 abstract description 13
- 230000002708 enhancing effect Effects 0.000 abstract description 10
- 230000008099 melanin synthesis Effects 0.000 abstract description 10
- 102000029816 Collagenase Human genes 0.000 abstract description 9
- 108060005980 Collagenase Proteins 0.000 abstract description 9
- 229960002424 collagenase Drugs 0.000 abstract description 9
- 210000002950 fibroblast Anatomy 0.000 abstract description 9
- 210000003491 skin Anatomy 0.000 description 61
- 230000006872 improvement Effects 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000049 pigment Substances 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 229920002498 Beta-glucan Polymers 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- GLNFSGHTGUQWMY-UHFFFAOYSA-N cyclopenta[c]pyran-4-carboxylic acid Chemical compound OC(=O)C1=COC=C2C=CC=C12 GLNFSGHTGUQWMY-UHFFFAOYSA-N 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 3
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000751065 Monotropa hypopitys Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NQRKYASMKDDGHT-UHFFFAOYSA-N (aminooxy)acetic acid Chemical compound NOCC(O)=O NQRKYASMKDDGHT-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000096284 Gynochthodes officinalis Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 206010042135 Stomatitis necrotising Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- LJSAJMXWXGSVNA-UHFFFAOYSA-N a805044 Chemical compound OC1=CC=C(O)C=C1.OC1=CC=C(O)C=C1 LJSAJMXWXGSVNA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000571 inhibitory effect on melanoma Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 201000008585 noma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 피부 주름 개선 및 미백용 조성물에 관한 것이다.
The present invention relates to a composition for skin wrinkle improvement and whitening.
콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포분할과 분화(유기체의 성장 혹은 상처 치유시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한, 근래에 들어 피부 노화에 대한 광범위한 연구가 발전되면서 피부에서의 콜라겐의 중요한 기능이 밝혀지고 있다. Collagen is a major substrate protein produced by skin fibroblasts and is present in extracellular epilepsy.Its important functions include mechanical firmness of skin, resistance of connective tissue and tissue binding, support of cell adhesion, cell division and differentiation. Induction of growth or wound healing) is known. This collagen is reduced by age and light aging by ultraviolet irradiation, which is known to be closely related to the wrinkle formation of the skin. In addition, in recent years, extensive research on aging of the skin has been developed an important function of collagen in the skin.
종래에는 콜라겐의 피부 보습 효과로부터 화장품에 콜라겐을 배합하는 제품들이 출시되어 있으나, 이들 화장품은 콜라겐을 피부 표면에 도포하는 것으로, 고분자인 콜라겐의 경피 흡수에 의한 보습작용을 기대할 수 없으므로 본질적인 피부 기능 개선이라고 말할 수 없다. Conventionally, products that combine collagen with cosmetics have been released from the skin moisturizing effect of collagen, but these cosmetics are applied to the surface of the collagen, and it is not expected to moisturize by the percutaneous absorption of collagen as a polymer, thereby improving the essential skin function. I can not say.
한편, 콜라겐 합성 촉진하여 주름 개선 효과를 나타내는 유효성분들이 알려져 있다. 예를 들어, 레티노산(retinoic acid), TGF(transforming growth factor)[비특허문헌 5], 동물 태반 유래의 단백질[특허문헌 1], 베튤린산(betulinic acid)[특허문헌 2], 클로렐라 추출물[특허문헌 3, 4] 등이 콜라겐 합성 촉진 물질로서 알려져 있다. 그러나, 상기 유효성분들은 피부 적용 시 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 피부의 콜라겐 합성을 촉진하여 피부 기능을 개선하는 효과를 기대할 수 없는 문제점이 있다. 따라서, 생체에 안전하고, 유효성분이 안정하며, 무엇보다도 기존의 콜라겐 합성 촉진 물질보다 효과가 우수한 주름 개선 활성을 지닌 성분의 개발이 절실히 요망되고 있다.
On the other hand, it is known that the active ingredients that promote the collagen synthesis to exhibit the wrinkle improvement effect. For example, retinoic acid, transforming growth factor (TGF) [non-patent document 5], protein derived from animal placenta [patent document 1], betulinic acid (betulinic acid) [patent document 2], chlorella extract [ Patent Documents 3 and 4 are known as collagen synthesis promoting substances. However, the active ingredients are limited in the amount of use due to safety problems such as irritation and redness when applying the skin, or there is a problem in that the effect of improving the skin function is not expected by substantially promoting collagen synthesis of the skin. Therefore, there is an urgent need for the development of components that are safe for the living body, the active ingredients are stable, and above all, the anti-wrinkle activity that is superior to the conventional collagen synthesis promoting substance.
또한, 희고 고운 피부를 갖고자 하는 것은 모든 사람의 한결같은 소망이다. 사람의 피부색은 피부 내 멜라닌(melanin)의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선이나 피로, 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 작용하여 도파(DOPA), 도파퀴논(dopaquinone)으로 바뀐 후 비효소적인 산화반응을 통해 만들어진다. 이와 같이, 멜라닌이 만들어지는 경로는 알려져 있으나, 티로시나제가 작용하는 이전 단계인 멜라닌 합성을 유도하는 메카니즘이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다.Also, to have white and fair skin is everyone's constant desire. Human skin color is genetically determined by the concentration and distribution of melanin in the skin, but is also influenced by environmental or physiological conditions such as sun ultraviolet rays, fatigue and stress. Melanin is produced through non-enzymatic oxidation after tyrosine, an amino acid, acts as an enzyme called tyrosinase to convert it into dopa and dopaquinone. As such, the pathway by which melanin is produced is known, but the mechanisms that induce melanin synthesis, the previous stages of tyrosinase action, are still unknown.
한편, 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다.
On the other hand, by inhibiting the synthesis of melanin pigment, not only can the skin tone be brightened to realize skin whitening, but also the improvement of skin hyperpigmentation such as blemishes and freckles due to ultraviolet rays, hormones or heredity.
이에, 본 발명자들은 모노트로페인(monotropein)이 피부 섬유아세포의 콜라겐 합성을 촉진하고, 콜라게나제 활성을 억제함으로써, 주름을 개선시키는 동시에, 멜라닌의 생성을 저해함으로써, 미백 효과를 가진다는 점을 확인하여 본 발명을 완성하게 되었다.Accordingly, the present inventors have found that monotropein has a whitening effect by promoting collagen synthesis of skin fibroblasts and inhibiting collagenase activity, thereby improving wrinkles and inhibiting melanin production. It confirmed and completed this invention.
따라서, 본 발명의 목적은 모노트로페인(monotropein)을 유효성분으로 함유하는 피부 주름 개선 및 미백용 조성물을 제공하는데 있다.
Accordingly, it is an object of the present invention to provide a composition for improving skin wrinkles and whitening containing monotropein as an active ingredient.
상기 과제를 해결하기 위한 수단으로서, 본 발명은As means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 주름 개선용 약학적 조성물을 제공한다. It provides a pharmaceutical composition for improving skin wrinkles comprising a compound represented by the formula (1) as an active ingredient.
[화학식 1][Formula 1]
상기 과제를 해결하기 위한 다른 수단으로서, 본 발명은 As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 주름 개선용 피부 외용제을 제공한다.
It provides a skin external preparation for improving skin wrinkles comprising the compound represented by the following formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.
It provides a cosmetic composition for improving skin wrinkles comprising a compound represented by the formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 주름 개선용 건강 식품을 제공한다.
It provides a health food for improving skin wrinkles comprising the compound represented by the formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 미백용 약학적 조성물을 제공한다.
It provides a whitening pharmaceutical composition comprising the compound represented by the following formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은 As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 미백용 피부 외용제을 제공한다.
To provide a whitening skin external preparation containing a compound represented by the formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 미백용 화장료 조성물을 제공한다.
It provides a cosmetic composition for whitening comprising a compound represented by the formula (1) as an active ingredient.
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 미백용 건강 식품을 제공한다.
It provides a whitening health food comprising the compound represented by the following formula (1) as an active ingredient.
본 발명에 따른 모노트로페인(monotropein)은 피부 섬유아세포의 콜라겐 합성을 촉진하고, 콜라게나제 활성을 억제하여 주름을 개선시키는 동시에, 멜라닌의 생성을 저해하여 미백 효과를 지님으로, 의약품, 화장료 또는 건강식품에 사용할 수 있다.
Monotropein according to the present invention promotes collagen synthesis of skin fibroblasts, inhibits collagenase activity, improves wrinkles, and inhibits the production of melanin, which has a whitening effect. Can be used for health foods.
이하, 본 발명의 구성을 구체적으로 설명한다.EMBODIMENT OF THE INVENTION Hereinafter, the structure of this invention is demonstrated concretely.
피부주름 개선 성분이 실제 피부에 적용 시 우수한 피부 주름 개선 효과를 발휘하기 위해서는 저농도에서 고활성의 주름 개선 활성을 나타내고, 피부를 투과하여 흡수되는 능력이 우수하며, 피부주름 개선 효과를 나타내기에 충분한 시간 동안 머무를 수 있도록 휘발성이 낮아야 한다. 또한, 조성물 또는 피부 상에서 활성 성분이 안정하게 유지되고, 의약이나 화장품으로의 제형화하기 용이하며, 피부에 안전해야 한다.In order for skin wrinkle improving ingredients to have excellent skin wrinkle improvement effect when applied to actual skin, it shows high activity of wrinkle improvement at low concentration, excellent ability to penetrate and absorb skin, and sufficient time to show skin wrinkle improvement effect. It must be low volatility so that it can stay for a while. In addition, the active ingredient on the composition or skin should remain stable, easy to formulate into medicines or cosmetics, and be safe for skin.
그러나, 공지의 피부주름 개선 성분 중 상기 특성을 모두 만족시키는 피부 주름 개선 성분은 흔치 않다. 예를 들어, 몇몇 주름 개선 성분들은 시험관 내 실험 시 저농도에서도 주름 개선 활성이 우수하나 피부를 투과하여 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어려우며, 친수성이 낮아 의약이나 화장품으로 제형화가 어렵다. 또한, 몇몇 피부 주름 개선 성분들은 열, 광, 또는 산소에 노출되었을 때 주름개선 성분이 분해되거나 다른 화합물로 변형되어 피부에 적용하기 전에 이미 주름 개선 효과가 사라지는 경우도 있다.However, among the known skin wrinkle improving ingredients, skin wrinkle improving ingredients satisfying all of the above properties are rare. For example, some wrinkle improving ingredients have excellent wrinkle improving activity even at low concentrations in vitro, but are difficult to apply to skin due to their poor ability to penetrate and absorb skin, and are difficult to formulate in medicine or cosmetics due to their low hydrophilicity. In addition, some skin wrinkle improving ingredients may be decomposed or transformed into other compounds when exposed to heat, light, or oxygen, so that the wrinkle improving effect is already lost before being applied to the skin.
하기 실시예에서 확인할 수 있는 바와 같이, 모노트로페인(monotropein)은 저농도에서 우수한 콜라게나제 활성 저해 효과 및 콜라겐 합성 촉진 효과를 나타낸다. 또한, 상기 모노트로페인(monotropein)은 우수한 멜라닌 생성 저해 효과를 나타낸다. 따라서, 상기 모노트로페인(monotropein)은 의약품 또는 화장품에서 주름 개선 효능 및 미백 효능을 나타내는 유효성분으로서 이용될 수 있다.As can be seen in the following examples, monotropein (monotropein) shows excellent collagenase activity inhibitory effect and collagen synthesis promoting effect at low concentration. In addition, the monotropein (monotropein) shows an excellent melanin production inhibitory effect. Therefore, the monotropein (monotropein) can be used as an active ingredient exhibiting wrinkle improvement and whitening efficacy in medicine or cosmetics.
따라서, 본 발명은 하기 화학식 1로 표현되는 화합물을 포함하는 피부 주름 개선 및 미백용 약학적 조성물을 제공한다:Accordingly, the present invention provides a pharmaceutical composition for skin wrinkle improvement and whitening comprising a compound represented by the following formula (1):
[화학식 1][Formula 1]
상기 화학식 1의 화합물의 화합물명은 Cyclopenta[c]pyran-4-carboxylicacid, 1-(b-D-glucopyranosyloxy)-1,4a,7,7a-tetrahydro-7-hydroxy-7-(hydroxymethyl)-,[1S-(1a,4aa,7b,7aa)] 또는 Cyclopenta[c]pyran-4-carboxylicacid, 1-(b-D-glucopyranosyloxy)-1,4a,7,7a-tetrahydro-7-hydroxy-7-(hydroxymethyl)-,(1S,4aS,7R,7aS)라 하며, 일명 모노트로페인(monotropein)이라 한다.The compound name of the compound of Formula 1 is Cyclopenta [c] pyran-4-carboxylicacid, 1- (bD-glucopyranosyloxy) -1,4a, 7,7a-tetrahydro-7-hydroxy-7- (hydroxymethyl)-, [1S- (1a, 4aa, 7b, 7aa)] or Cyclopenta [c] pyran-4-carboxylicacid, 1- (bD-glucopyranosyloxy) -1,4a, 7,7a-tetrahydro-7-hydroxy-7- (hydroxymethyl)-, It is called (1S, 4aS, 7R, 7aS), also known as monotropein (monotropein).
상기 화학식 1의 화합물은 합성하여 이용하거나, 시판되고 있는 화합물을 이용할 수 있다. The compound of Formula 1 may be synthesized or used a commercially available compound.
본 발명의 피부 주름 개선 및 미백 증진용 약학적 조성물은 상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염을 포함할 수 있다.The pharmaceutical composition for improving skin wrinkles and enhancing whitening of the present invention may include a pharmaceutically acceptable salt of the compound of Formula 1.
상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염은 유기산 또는 무기산을 이용하여 형성된 산 부가염일 수 있으며, 상기 유기산은, 예를 들면 포름산, 아세트산, 프로피온산, 락트산, 부티르산, 이소부티르산, 트리플루오로아세트산, 말산, 말레산, 말론산, 푸마르산, 숙신산, 숙신산 모노아미드, 글루탐산, 타르타르산, 옥살산, 시트르산, 글리콜산, 글루쿠론산, 아스코르브산, 벤조산, 프탈산, 살리실산, 안트라닐산, 디클로로아세트산, 아미노옥시 아세트산, 벤젠술폰산, p-톨루엔술폰산 및 메탄술폰산계 염을 포함하며 무기산은 예를 들면 염산, 브롬산, 황산, 인산, 질산, 탄산 및 붕산계 염을 포함한다. 바람직하게는 염산염 또는 아세트산염 형태일 수 있으며, 보다 바람직하게는 염산염 형태일 수 있다.The pharmaceutically acceptable salt of the compound of Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid or trifluoroacetic acid. , Malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid And benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid salts and inorganic acids include, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.
상기 언급된 산 부가염은 a) 상기 화학식 1의 화합물 및 산을 직접 혼합하거나, b) 이들 중 한 가지를 용매 또는 함수 용매 중에 용해시키고 혼합시키거나, 또는 c) 화학식 1의 화합물을 용매 또는 수하 용매 중의 산에 위치시키고 이들을 혼합하는 일반적인 염 제조방법으로 제조된다.The above-mentioned acid addition salts may be a) directly mixing the compound of formula 1 and an acid, b) dissolving and mixing one of them in a solvent or a hydrous solvent, or c) solvent or submerging the compound of formula 1 It is prepared by a general salt preparation method which is placed in an acid in a solvent and mixed with them.
위와는 별도로 추가적으로 염이 가능한 형태는 가바염, 가바펜틴염, 프레가발린염, 니코틴산염, 아디페이트염, 헤미말론산염, 시스테인염, 아세틸시스테인염, 메티오닌염, 아르기닌염, 라이신염, 오르니틴염, 아스파르트산염 등이 있다.
In addition to the above, salts that can be additionally salted are gabar salt, gabapentin salt, pregabalin salt, nicotinate, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt, Aspartate.
또한, 본 발명의 상기 화학식 1의 화합물을 의약품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 주름 개선 성분, 탄력 증진 성분 또는 미백 성분을 포함할 수 있을 것이다. 추가적인 피부 주름 개선 성분, 탄력 증진 성분 및 미백 성분을 포함하게 되면 본 발명의 조성물의 주름 개선, 탄력 증진 및 미백 증진 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 한 구체예에서, 상기 조성물은 당업계에 공지된 주름 개선 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베튤린산 및 클로렐라 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 피부 주름 개선 성분을 추가로 포함할 수 있으며, 또한, 공지된 미백 개선 성분으로서, 코지산(Kojic acid), 알부틴(Arbutin), 하이드로퀴논(Hydroquinone) 및 비타민-C(L-Ascorbic acid)으로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 피부 미백 개선 성분을 추가로 포함할 수 있다. 추가의 피부 주름 및 미백 개선 성분은 전체 조성물 중량에 대하여 0.0001 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 콜라겐 합성 촉진 활성, 멜라닌 생성 억제, 피부 안전성 및 상기 화학식 1의 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.
In addition, when using the compound of Formula 1 of the present invention as a medicine, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may include known skin wrinkle improving ingredients, elasticity enhancing ingredients or whitening ingredients. The inclusion of additional skin wrinkle improving ingredients, elasticity enhancing ingredients and whitening ingredients may further enhance the wrinkle improving, elasticity enhancing and whitening enhancing effects of the compositions of the present invention. When the ingredient is added, skin safety, ease of formulation, and stability of the active ingredients may be considered. In one embodiment of the invention, the composition is a wrinkle improving component known in the art, one or two or more selected from the group consisting of retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract It may further comprise a skin wrinkle improving ingredient, and also known as a whitening improving ingredient, consisting of Kojic acid (Kojic acid), arbutin (Arbutin), hydroquinone (Hydroquinone) and vitamin-C (L-Ascorbic acid) It may further comprise one or two or more skin lightening improving ingredients selected from the group consisting of. Additional skin wrinkle and whitening improving ingredients may be included in 0.0001 to 10% by weight based on the total weight of the composition, the content range of the collagen synthesis promoting activity, melanin production inhibition, skin safety and when formulating the compound of Formula 1 May be adjusted according to requirements such as ease of use.
또한, 본 발명의 피부 주름 개선 및 미백용 약학적 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다. In addition, the pharmaceutical composition for skin wrinkle improvement and whitening of the present invention may further comprise a pharmaceutically acceptable carrier.
약학적으로 허용되는 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 슈크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain various components such as buffers, sterile water for injection, general saline or phosphate buffered saline, sucrose, histidine, salts, polysorbates and the like.
본 발명의 약학적 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 의약품 제제의 형태, 예를 들어, 임상 투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. The pharmaceutical composition of the present invention may be administered orally or parenterally, and may be administered in the form of a general pharmaceutical preparation, for example, in various dosage forms, orally and parenterally, during clinical administration. , Diluents or excipients such as extenders, binders, wetting agents, disintegrants, surfactants and the like.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in the pharmaceutical composition of the present invention, for example, starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin and the like.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral use include suspensions, solutions, emulsions, syrups, and the like, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 명세서에서, '주름 개선'이라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present specification, the 'wrinkle improvement' refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating wrinkles already generated.
본 발명의 약학적 조성물은 유효량의 상기 화학식 1의 화합물을 포함할 때 바람직한 주름 개선 효과, 탄력 증진 효과 및 미백 개선 효과를 제공할 수 있다. 본 발명에 있어서, '유효량'이라 함은 피부의 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시킬 수 있으며, 멜라닌의 생성을 억제 또는 저해하는 화합물의 양을 의미한다. 본 발명의 조성물에 포함되는 상기 화학식 1의 화합물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 피부의 주름 생성, 탄력 감소, 기미 등에 따른 피부과적 치료를 위한 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 화학식 1의 화합물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 내지 6 회 투여될 수 있다. The pharmaceutical composition of the present invention may provide a desirable wrinkle improvement effect, elasticity enhancement effect and whitening improvement effect when an effective amount of the compound of Formula 1 is included. In the present invention, the "effective amount" refers to the amount of the compound that can inhibit or inhibit the generation of wrinkles on the skin, or can alleviate the wrinkles already produced, and inhibit or inhibit the production of melanin. The effective amount of the compound of formula 1 included in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, the time it stays on the skin, and the like. For example, when the composition is commercialized as a medicament for dermatological treatment due to wrinkle formation, elasticity reduction, and blemishes of the skin, the compound of Formula 1 may be used at a higher concentration than when it is commercialized as a cosmetic product to be applied to the skin on a daily basis. It may include. Therefore, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, 1 to 1 day, based on the amount of the compound of Formula 1 It may be administered six times.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 미백용 피부 외용제를 제공한다.The present invention also provides a skin external preparation for skin wrinkle improvement and whitening comprising the compound of Formula 1.
상기 화학식 1의 화합물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the compound of Formula 1 is used as an external preparation for skin, it is further added to fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants. Common in water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for the skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as. The components can also be introduced in amounts commonly used in the field of dermatology.
상기 화학식 1의 화합물이 피부 외용제 제형으로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제와 같은 제형을 가질 수 있으며, 상기 화학식 1의 화합물의 함량은 전체 조성물 대비 0.0001 내지 10 중량%, 구체적으로는 0.001 내지 1 중량%일 수 있다.
When the compound of Formula 1 is provided as an external preparation for skin, it is not limited thereto, and may have a formulation such as an ointment, a patch, a gel, a cream, or a spray, and the content of the compound of Formula 1 is 0.0001 to the total composition. 10 weight percent, specifically 0.001 to 1 weight percent.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 미백용 화장료를 제공한다.The present invention also provides a cosmetic for improving skin wrinkles and whitening comprising the compound of Formula 1.
상기 화학식 1의 화합물을 화장품으로 사용하는 경우, 상기 화학식 1의 화합물을 유효성분으로 함유하여 제조되는 화장품은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수, 훼이셜 로션, 바디로션 등과 같은 유액, 영양 크림, 수분 크림, 아이 크림 등과 같은 크림, 에센스, 화장연고, 스프레이, 젤, 팩, 선 스크린, 메이크업 베이스, 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션, 파우더, 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제, 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. When the compound of Formula 1 is used as a cosmetic, the cosmetic prepared by containing the compound of Formula 1 as an active ingredient may be prepared in the form of a general emulsion formulation and solubilized formulation. For example, lotions such as flexible lotions or nourishing lotions, emulsions such as facial lotions, body lotions, creams such as nourishing creams, moisture creams, eye creams, essences, cosmetic ointments, sprays, gels, packs, sunscreens, makeup bases, liquids Formulations such as foundations, powders, cleansing creams, cleansing lotions, makeup removers such as cleansing oils, cleansing foams, soaps, body washes and the like.
또한, 상기 화장료는 상기 화학식 1의 화합물에 추가로 화장료 조성물에 통상적으로 사용되는 안저화제, 용해화제, 비타민, 안료 또는 향료 등의 보조제 및 담체를 추가로 포함할 수 있다. 예컨대, 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetics may further include auxiliaries and carriers such as a stabilizer, solubilizer, vitamins, pigments or flavorings commonly used in cosmetic compositions in addition to the compound of Formula 1. For example, fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, Commonly used in the field of cosmetics such as metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics. It may contain an adjuvant used.
상기 화학식 1의 화합물은 화장품으로 제품화되는 경우에 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제, 세정제 등과 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 동안 피부에 머무르게 되는 화장수, 유액, 크림, 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 화학식 1의 화합물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 화학식 1의 화합물을 전체 조성물 중량에 대하여 0.0001 내지 10 중량%, 보다 구체적으로 0.001 내지 1 중량%로 포함할 수 있다. 본 발명의 조성물이 상기 화학식 1의 화합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 주름 개선 및 미백 개선 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다. The compound of Formula 1 may be a relatively high concentration of the compound of Formula 1 in the case of a wash-off type cosmetic such as a make-up remover, a detergent, etc., in which the active ingredient stays on the skin within a short time when it is commercialized. It may include. On the other hand, in the case of a leave-on type cosmetic such as a lotion, an emulsion, a cream, an essence, etc., in which the active ingredient stays on the skin for a long time, the compound of Chemical Formula 1 has a lower concentration than the wash-off type cosmetic. It may be included. Although not limited thereto, in one embodiment of the present invention, the composition may include the compound of Formula 1 as 0.0001 to 10% by weight, more specifically 0.001 to 1% by weight based on the total weight of the composition. When the composition of the present invention comprises less than 0.0001% by weight of the compound of formula (1) can not expect sufficient wrinkle improvement and whitening improvement effect, when containing more than 10% by weight unwanted reactions such as allergy or There may be a problem with the safety of the skin is to prevent this.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 주름 개선 및 미백용 건강식품에 관한 것이다.The present invention also relates to skin wrinkle improvement and whitening health food comprising the compound of Formula 1.
본 명세서에서 "건강식품" 이란, 상기 화학식 1의 화합물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있다.In the present specification, "health food" is a food prepared by adding the compound of Chemical Formula 1 to food materials such as beverages, teas, spices, gums, confectionery, encapsulated, powdered, suspensions, etc. It means to bring a certain effect, but unlike the general medicine has the advantage that there are no side effects that can occur when taking a long-term use of the drug as a raw material.
이와 같이 하여 얻어지는 본 발명의 건강식품은, 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 주름 개선, 탄력 증진 및 미백 개선 효과를 기대할 수 있어 매우 유용하다.Since the health food of the present invention thus obtained can be consumed on a daily basis, high skin wrinkle improvement, elasticity improvement and whitening improvement effect can be expected, which is very useful.
상기 화학식 1의 화합물을 식품첨가물로 사용하는 경우, 상기 화학식 1의 화합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시 본 발명의 조성물은 전체 조성물 대비 0.0001 내지 10 중량%, 구체적으로는 0.001 내지 1 중량%의 함량으로 첨가될 수 있다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다. When the compound of Formula 1 is used as a food additive, the compound of Formula 1 may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). In general, the composition of the present invention in the manufacture of food or beverage may be added in an amount of 0.0001 to 10% by weight, specifically 0.001 to 1% by weight relative to the total composition. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the substance may be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, teas, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.
본 발명의 건강음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토오스, 슈크로오스와 같은 이당류; 덱스트린, 사이클로덱스트린과 같은 다당류; 또는 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강음료 100 mL 당 일반적으로 약 0.01 내지 0.04 g, 바람직하게는 약 0.02 내지 0.03 g 이다.The health beverage of the present invention may contain various flavors or natural carbohydrates and the like as additional ingredients, as in general beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Or sugar alcohols such as xylitol, sorbitol, and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the health beverage of the present invention.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages.
그 밖에 본 발명의 건강식품은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 건강식품 100 중량부당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the health food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<참조예 1> 화학식 1의 화합물의 정보 Reference Example 1 Information of the Compound of Formula 1
물질명: monotropein Material Name: monotropein
Cyclopenta[c]pyran-4-carboxylicacid, 1-(b-D-glucopyranosyloxy)-1,4a,7,7a-tetrahydro-7-hydroxy-7-(hydroxymethyl)-,[1S-(1a,4aa,7b,7aa)]-;Cyclopenta [c] pyran-4-carboxylicacid, 1- (bD-glucopyranosyloxy) -1,4a, 7,7a-tetrahydro-7-hydroxy-7- (hydroxymethyl)-, [1S- (1a, 4aa, 7b, 7aa )]-;
Cyclopenta[c]pyran-4-carboxylicacid, 1-(b-D-glucopyranosyloxy)-1,4a,7,7a-tetrahydro-7-hydroxy-7-(hydroxymethyl)-,(1S,4aS,7R,7aS)-; Cyclopenta [c] pyran-4-carboxylicacid, 1- (b-D-glucopyranosyloxy) -1,4a, 7,7a-tetrahydro-7-hydroxy-7- (hydroxymethyl)-, (1S, 4aS, 7R, 7aS)-;
NSC 291303;NSC 88926; NSC 291303; NSC 88926;
CAS No.: 5945-50-6CAS No .: 5945-50-6
구입처: alibaba Where to buy: alibaba
기원식물: Morinda officinalis
Plant of Origin: Morinda officinalis
실시예Example 1: 콜라겐 합성 효과 1: collagen synthesis effect
하기 표 1의 물질을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 콜라겐 합성 촉진 효과를 실험하였다. The substances shown in Table 1 below were added to the culture solution of human-derived fibroblasts to test collagen synthesis promoting effects at the cellular level.
합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT)를 이용하여 정량하였다. 실험전 인간 유래 섬유아세포를 대상으로 실험물질의 농도 10ppm, 1ppm 및 0.1ppm에서 세포독성을 평가(섬유아세포를 배양하여 MTT시험을 하는 방법[참고문헌: Mossman T. (1983). Rapid Colorimetric Assay for Cellular Growth & Survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63])하였으며, 세포독성이 없는 농도를 선정하여 콜라겐합성능을 평가하였다. The synthesis of collagen was quantified using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT). Evaluation of cytotoxicity at concentrations of 10ppm, 1ppm and 0.1ppm of human testosterone-derived fibroblasts before experiment (method of culturing fibroblasts for MTT test [Mossman T. (1983). Rapid Colorimetric Assay for Cellular Growth & Survival: application to proliferation & cytotoxicity assays.Journal of Immunological Methods 65, 55-63]).
실험에서 모노트로페인의 최종 농도는 0.1 ppm 및 1 ppm으로 하였으며, 각각의 시료는 인간 섬유아세포의 배양배지에 첨가하여 1일간 배양한 후, 배양액을 취하여 PICP EIA 키트로 각 농도에서의 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다. 효과의 비교를 위하여 아무것도 첨가하지 않은 섬유아세포의 배양 배지(대조군)와 비타민 C를 최종 농도 52.8 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성량은 UV 흡광도로서 측정하였으며, 콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량 비율로 계산하고, 그 결과를 하기 표 1에 정리하였다.
In the experiment, the final concentrations of monotropine were 0.1 ppm and 1 ppm, and each sample was added to the culture medium of human fibroblasts, incubated for 1 day, and then the culture medium was taken, and the degree of collagen synthesis at each concentration was obtained using PICP EIA kit. Was measured at 450 nm using a spectrophotometer. For comparison of the effects, the degree of collagen synthesis was measured by the same method for the culture medium (control) of the fibroblasts to which nothing was added and the sample to which the vitamin C was added at a final concentration of 52.8 μg / ml. Collagen production was measured as UV absorbance, the collagen production increase rate was calculated as the ratio of collagen production relative to the control, the results are summarized in Table 1 below.
52.8 ㎍/mlVitamin C
52.8 μg / ml
상기 표 1의 결과에서 볼 수 있듯이, 모노트로페인은 대조군에 비해 우수한 콜라겐 합성 효과를 나타내며, 특히, 1 ppm 사용했을 경우, 일반적으로 콜라겐 합성 능력이 있는 것으로 알려진 비타민 C를 적용한 경우 보다 더 우수한 콜라겐 합성 효과를 발휘하였다.
As can be seen from the results of Table 1, monotrophane shows a superior collagen synthesis effect compared to the control group, in particular, when used at 1 ppm, collagen is better than the case of applying vitamin C, which is generally known to have collagen synthesis ability Synthetic effect was exerted.
실시예Example 2: 2: 콜라게네이즈Collagenase 활성 억제 효과 Activity inhibitory effect
하기 표 2의 물질에 대하여 콜라게나제 활성 억제 효과를 다음과 같이 확인하였다.It was confirmed as follows the collagenase activity inhibitory effect on the material of Table 2.
실험전 인간 유래 섬유아세포를 대상으로 실험물질의 농도 10ppm, 1ppm, 0.1ppm, 0.01ppm, 0.001ppm에서 세포독성을 평가(섬유아세포를 배양하여 MTT시험을 하는 방법[참고문헌: Mossman T. (1983). Rapid Colorimetric Assay for Cellular Growth & Survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63])하였으며, 세포독성이 없는 농도를 선정하여 콜라게나제 평가법를 수행하였다. Evaluation of cytotoxicity at concentrations of 10ppm, 1ppm, 0.1ppm, 0.01ppm, and 0.001ppm of human-derived fibroblasts before experiment (method of culturing fibroblasts for MTT test [Reference: Mossman T. (1983) Rapid Colorimetric Assay for Cellular Growth & Survival: application to proliferation & cytotoxicity assays.Journal of Immunological Methods 65, 55-63]).
인간 정상 피부 세포인 섬유아세포를 24-웰 마이크로 플레이트에 각 웰당 2.5× 104 세포가 되도록 접종하고, 10% 혈청 DMEM 배지 및 37℃의 조건에서 24시간 동안 배양한 후 10% 혈청 DMEM 배지를 제거하고 인산완충용액으로 1회 세척하고, 모노트로페인을 농도별로 첨가한 무혈청 DMEM 배지 및 대조군으로 모노트로페인이 포함되지 않은 무혈청 DMEM 배지에서 30분 동안 추가로 배양하였다. 시료 처리 30분 후 MMP-1 을 증가시키는 것으로 알려진 물질인 TNF-α(tumor necrosis factor-α) 50ng/ml로 자극 후 24시간 배양하였다. 이때 TNF-α 무처리군과 처리군은 모노트로페인이 포함되지 않은 대조군 중 TNF-α를 처리하지 않은 무처리군과 TNF-α를 처리한 처리군으로 하였다. Fibroblasts, which are human normal skin cells, were seeded in a 24-well microplate at 2.5 × 10 4 cells per well, incubated for 24 hours at 10% serum DMEM medium and 37 ° C., and then 10% serum DMEM medium was removed. Once washed with phosphate buffer solution, and further incubated for 30 minutes in serum-free DMEM medium to which monotropes were added by concentration and serum-free DMEM medium containing no monotropes as a control. Thirty minutes after stimulation with 50ng / ml of TNF-α (tumor necrosis factor-α), a substance known to increase MMP-1 after 30 minutes of sample treatment. In this case, the TNF-α untreated group and the treated group were treated with the TNF-α untreated group and the TNF-α treated group among the control groups that did not contain monotropes.
각 웰의 상층액을 모아 MMP-1 분석 킷트(Amersham, 미국)를 이용하여 새로 합성된 MMP-1의 양(ng/㎖)을 측정하고, 콜라게나제 활성 저해율은 하기 수학식 1에 따라 MMP-1 생성억제율(%)을 계산하였으며, 그 결과는 하기 표 2에 나타낸 바와 같다. 대조군의 MMP-1의 양은 TNF처리군의 MMP-1양을 의미하며 실험군의 MMP-1의 양은 각각 농도로 물질이 첨가된 군을 말한다.
The supernatant of each well was collected to measure the amount (ng / ml) of newly synthesized MMP-1 using an MMP-1 assay kit (Amersham, USA), and the collagenase activity inhibition rate was determined according to Equation 1 below. -1 generation inhibition rate (%) was calculated, the results are shown in Table 2 below. The amount of MMP-1 in the control group means the amount of MMP-1 in the TNF treatment group, and the amount of MMP-1 in the experimental group refers to the group to which the substance is added at each concentration.
[수학식 1][Equation 1]
상기 표 2를 통해 모노트로페인이 콜라게나제 활성을 저해하는데 효과가 있음을 확인할 수 있다.
It can be seen from Table 2 that the monotropine is effective in inhibiting collagenase activity.
실시예Example 3: 미백 효과 확인 3: Check the whitening effect
멜라닌 생성 저해 효과 확인Confirmation of melanin production inhibitory effect
모노트로페인을 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여 세포 수준에서의 미백 효과를 실험하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980).Monotrophin was added to the culture of mouse B-16 mouse melanoma cells to test the whitening effect at the cellular level (Lotan R., Lotan D. Cancer Res. 40: 3345-3350, 1980). .
실험전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백평가를 수행하였다.Before the experiment, rat melanoma cells were evaluated for toxicity and non-toxic concentrations were selected for whitening evaluation.
모노트로페인을 배양액에 최종농도가 0.01ug/ml, 0.1ug/ml, 1ug/ml, 10ug/ml가 되도록하여 실험하였으며, 대조군인 알부틴은 200ug/ml가 되도록 배지에 첨가하여 각각 B-16멜라노마 세포에 처리하여 3일간 배양하였다. The monotropine was tested in the culture medium so that the final concentration was 0.01ug / ml, 0.1ug / ml, 1ug / ml, 10ug / ml, and the control arbutin was added to the medium so that 200ug / ml was added to the B-16 mel, respectively. The cells were treated with noma cells and cultured for 3 days.
이후, 세포들을 트립신(trypsin)처리하여 배양용기로부터 떼어내 원심분리한 후 멜라닌을 추출하였다. 떠에낸 세포는 수산화 나트륨 용액(1N 농도) 1ml를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여, 400 nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. Thereafter, cells were trypsinized, removed from the culture vessel, centrifuged, and melanin was extracted. The suspended cells were added with 1 ml of sodium hydroxide solution (1 N concentration), boiled for 10 minutes to dissolve the melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.
상기 멜라닌 양은 단위 세포수당(106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 생성량을 저해율(%)로 계산하고 그 결과를 표 3에 정리하였다. The melanin amount was measured by the absorbance of the unit cell count (10 6 cells), the relative melanin production relative to the control group was calculated as the inhibition rate (%) and the results are summarized in Table 3.
실험은 3번 반복된 것이다.
The experiment was repeated three times.
상기 표3의 결과에서 볼 수 있듯이, 모노트로페인을 1 mg/ml 이상에서 기존에 알려진 미백 물질인 알부틴(Arbutin)과 비교할 때 배양된 쥐의 멜라노마 세포에 대하여 월등히 우수한 멜라닌 생성 억제능이 있음을 알 수 있다.
As can be seen from the results of Table 3, when compared with monobutane, Arbutin, a previously known whitening substance at 1 mg / ml or more, it has an excellent melanin production inhibitory effect on melanoma cells in cultured rats. Able to know.
제제예 1: 약학적 제제의 제조 Formulation Example 1 Preparation of Pharmaceutical Formulation
1. 산제의 제조1. Manufacturing of powder
화학식 1의 화합물 0.001g0.001 g of compound of Formula 1
유당 1g 1g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
화학식 1의 화합물 0.2㎎0.2 mg of compound of Formula 1
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎Lactose 100mg
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of Capsule
화학식 1의 화합물 0.2㎎0.2 mg of compound of Formula 1
옥수수전분 100㎎100 mg of corn starch
유 당 100㎎Lactose 100mg
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
4. 환의 제조4. Manufacture of rings
화학식 1의 화합물 0.003 g0.003 g of compound of Formula 1
유당 1.5 gLactose 1.5 g
글리세린 1 g1 g of glycerin
자일리톨Xylitol 0.5 g 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
5. 과립의 제조5. Manufacture of granules
화학식 1의 화합물 2 ㎎2 mg of compound of formula 1
대두 추출물 50 ㎎Soybean Extract 50mg
포도당 200 ㎎Glucose 200 mg
전분 600 ㎎ Starch 600 mg
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, and then filled in fabric.
제제예Formulation example 2: 화장품의 제조 2: manufacture of cosmetics
1. 유연화장수(스킨로션)의 제조1. Preparation of Soft Cosmetics (Skin Lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 유연화장수를 통상의 방법에 따라 제조하였다.Like the following composition, a flexible longevity containing the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량%0.1 wt% of a compound of Formula 1
베타-1,3-글루칸 1.0 중량%Beta-1,3-Glucan 1.0 wt%
부틸렌글리콜 2.0 중량%Butylene Glycol 2.0 wt%
프로필렌글리콜 2.0 중량%Propylene Glycol 2.0 wt%
카르복시비닐폴리머 0.1 중량%Carboxy vinyl polymer 0.1 wt%
피이지-12 노닐페닐에테르 0.2 중량%Fiji-12 nonylphenyl ether 0.2% by weight
폴리솔베이트80 0.4 중량%Polysorbate 80 0.4 wt%
에탄올 10.0 중량%Ethanol 10.0 wt%
트리에탄올아민 0.1 중량%0.1% by weight of triethanolamine
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
2. 영양화장수(밀크로션)의 제조2. Preparation of Nutrients (Milk Lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양화장수를 통상의 방법에 따라 제조하였다.As shown in the following composition, nutrient longevity containing the compound of Formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량%0.1 wt% of a compound of Formula 1
베타-1,3-글루칸 1.0 중량%Beta-1,3-Glucan 1.0 wt%
밀납 4.0 중량%Beeswax 4.0 wt%
폴리솔베이트60 1.5 중량%Polysorbate60 1.5 wt%
솔비탄세스퀴올레이트 1.5 중량%Sorbanthesquioleate 1.5 wt%
유동파라핀 0.5 중량%0.5% by weight of liquid paraffin
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / Capric Triglycerides 5.0 wt%
글리세린 3.0 중량%Glycerin 3.0 wt%
부틸렌글리콜 3.0 중량%Butylene Glycol 3.0 wt%
프로필렌글리콜 3.0 중량%Propylene Glycol 3.0 wt%
카르복시비닐폴리머 0.1 중량%Carboxy vinyl polymer 0.1 wt%
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
3. 영양크림의 제조3. Manufacture of nutritional cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.As in the following composition, a nourishing cream containing the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.2중량%0.2 wt% of a compound of Formula 1
베타-1,3-글루칸 5.0 중량%Beta-1,3-Glucan 5.0 wt%
밀납 10.0 중량%Beeswax 10.0 wt%
폴리솔베이트60 1.5 중량%Polysorbate60 1.5 wt%
피이지 60 경화피마자유 2.0 중량%Sebum 60 Cured Castor Oil 2.0 wt%
솔비탄세스퀴올레이트 0.5 중량%0.5 wt% sorbitan sesquioleate
유동파라핀 10.0 중량%10.0% by weight of liquid paraffin
스쿠알란 5.0 중량%Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / Capric Triglycerides 5.0 wt%
글리세린 5.0 중량%Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량%Butylene Glycol 3.0 wt%
프로필렌글리콜 3.0 중량%Propylene Glycol 3.0 wt%
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
4. 마사지크림의 제조4. Preparation of Massage Cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 마사지크림을 통상의 방법에 따라 제조하였다.As in the following composition, a massage cream containing a compound of Formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량%0.1 wt% of a compound of Formula 1
베타-1,3-글루칸 3.0 중량%Beta-1,3-Glucan 3.0 wt%
밀납 10.0 중량%Beeswax 10.0 wt%
폴리솔베이트60 1.5 중량%Polysorbate60 1.5 wt%
피이지 60 경화피마자유 2.0 중량%Sebum 60 Cured Castor Oil 2.0 wt%
솔비탄세스퀴올레이트 0.8 중량%Sorbanthesquioleate 0.8 wt%
유동파라핀 40.0 중량%40.0% by weight of liquid paraffin
스쿠알란 5.0 중량%Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 4.0 중량%Caprylic / Capric Triglyceride 4.0 wt%
글리세린 5.0 중량%Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량%Butylene Glycol 3.0 wt%
프로필렌글리콜 3.0 중량%Propylene Glycol 3.0 wt%
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
5. 팩의 제조5. Manufacture of pack
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다.As in the following composition, a pack containing the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.2 중량%0.2 wt% of a compound of Formula 1
베타-1,3-글루칸 1.0 중량%Beta-1,3-Glucan 1.0 wt%
폴리비닐알콜 13.0 중량%Polyvinyl Alcohol 13.0 wt%
소듐카르복시메틸셀룰로오스 0.2 중량%Sodium Carboxymethyl Cellulose 0.2% by weight
글리세린 5.0 중량%Glycerin 5.0 wt%
알란토인 0.1 중량%Allantoin 0.1 wt%
에탄올 6.0 중량%Ethanol 6.0 wt%
피이지 -12 노닐페닐에테르 0.3 중량%0.3% by weight of sebum-12 nonylphenyl ether
폴리솔베이트 60 0.3 중량%Polysorbate 60 0.3 wt%
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
제제예Formulation example 3: 3: 피부외용제의External skin preparations 제조 Produce
1. 젤의 제조1. Preparation of Gel
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 젤을 통상의 방법에 따라 제조하였다.As in the following composition, a gel containing the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량%0.1 wt% of a compound of Formula 1
베타-1,3-글루칸 0.1 중량%Beta-1,3-Glucan 0.1 wt%
에틸렌디아민초산나트륨 0.05 중량%0.05% by weight of ethylenediamine sodium acetate
글리세린 5.0 중량%Glycerin 5.0 wt%
카르복시비닐폴리머 0.3 중량%Carboxy vinyl polymer 0.3 wt%
에탄올 5.0 중량%Ethanol 5.0 wt%
피이지-60 경화피마자유 0.5 중량%Fiji-60 Cured Castor Oil 0.5 wt%
트리에탄올아민 0.3 중량%0.3% by weight of triethanolamine
방부제 0.05 중량% 0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
2. 연고의 제조2. Manufacture of ointments
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.As shown in the following composition, an ointment containing the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.5중량%0.5% by weight of compound of formula 1
베타-1,3-글루칸 10.0 중량%Beta-1,3-Glucan 10.0 wt%
밀납 10.0 중량%Beeswax 10.0 wt%
폴리솔베이트60 5.0 중량%Polysorbate 60 5.0 wt%
피이지 60 경화피마자유 2.0 중량%Sebum 60 Cured Castor Oil 2.0 wt%
솔비탄세스퀴올레이트 0.5 중량%Sorbanthesquioleate 0.5 wt%
바셀린 5.0 중량%Vaseline 5.0 wt%
유동파라핀 10.0 중량%10.0% by weight of liquid paraffin
스쿠알란 5.0 중량%Squalane 5.0 wt%
쉐어버터 3.0 중량%Shea Butter 3.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / Capric Triglycerides 5.0 wt%
글리세린 10.0 중량%Glycerin 10.0 wt%
프로필렌글리콜 10.2 중량%Propylene Glycol 10.2 wt%
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제 0.05 중량%0.05 wt% preservative
색소 0.05 중량%0.05% by weight of pigment
향료 0.05 중량%0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100% by weight
3. 국소투여용 약제(겔 연고제) 의 제조3. Preparation of Topical Drug (Gel Ointment)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 겔 연고제를 통상의 방법에 따라 제조하였다.As the following composition, a gel ointment comprising the compound of formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.5 중량%0.5% by weight of compound of formula 1
베타-1,3-글루칸 10.0 중량%Beta-1,3-Glucan 10.0 wt%
폴리아크릴산(Carbopol 940) 1.5 중량%1.5% by weight of polyacrylic acid (Carbopol 940)
이소프로판올 5.0 중량%Isopropanol 5.0 wt%
헥실렌글리콜 25.0 중량%Hexylene glycol 25.0 wt%
트리에탄올아민 1.7 중량%Triethanolamine 1.7 wt%
탈이온수 to 100 중량%
Deionized water to 100% by weight
4. 국소 투여용 약제(패취제)의 제조4. Preparation of medicament (patch) for topical administration
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 패취제를 통상의 방법에 따라 제조하였다.As in the following composition, a patch containing the compound of Formula 1 as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.5 중량%0.5% by weight of compound of formula 1
베타-1,3-글루칸 3.0 중량%Beta-1,3-Glucan 3.0 wt%
헥실렌글리콜 20.0 중량% Hexylene glycol 20.0 wt%
디에틸아민 0.7 중량%Diethylamine 0.7 wt%
폴리아크릴산(Carbopol 934P) 1.0 중량%1.0% by weight of polyacrylic acid (Carbopol 934P)
아황산나트륨 0.1 중량%Sodium sulfite 0.1 wt%
폴리옥시에틸렌라우릴에테르(E.O=9) 1.0 중량%1.0 weight% of polyoxyethylene lauryl ether (E.O = 9)
폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) 1.0 중량%1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)
점성의 파라핀 오일 2.5 중량%Viscous paraffin oil 2.5% by weight
카프릴산에스테르/카프르산에스테르(Cetiol LC) 2.5 중량%Caprylic acid ester / capric acid ester (Cetiol LC) 2.5% by weight
폴리에틸렌글리콜400 3.0 중량%Polyethylene glycol 400 3.0 wt%
탈이온수 to 100 중량%
Deionized water to 100% by weight
제제예Formulation example 4: 식품의 제조 4: manufacture of food
본 발명의 화학식 1의 화합물을 포함하는 식품들을 다음과 같이 제조하였다.Food containing the compound of formula 1 of the present invention was prepared as follows.
1. 밀가루 식품의 제조1. Manufacture of Flour Food
상기 화학식 1의 화합물 0.05 ~ 1.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강식품을 제조하였다.
0.05 to 1.0 parts by weight of the compound of Formula 1 was added to the flour, and using the mixture to prepare bread, cake, cookies, crackers and noodles to prepare a health food.
2. 유제품(dairy products)의 제조2. Manufacturing of Dairy Products
상기 화학식 1의 화합물 0.2 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
0.2 parts by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
3. 선식의 제조3. Manufacture of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 상기 화학식 1의 화합물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The compound of Chemical Formula 1 was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 화학식 1의 화합물의 건조분말을 혼합 분말 100 중량부에 대하여 다음의 비율로 배합하여 제조하였다.The dry powders of the grains, seeds and the compound of formula 1 prepared above were prepared by blending the powders in 100 parts by weight in the following ratio.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
화학식 1의 화합물(0.1 중량부),Compound of formula 1 (0.1 parts by weight),
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 Foxglove (0.5
중량부Weight portion
) )
제제예Formulation example 5: 음료의 제조 5: manufacture of beverages
1. 건강음료의 제조1. Manufacture of health drinks
화학식 1의 화합물 0.1 ㎎0.1 mg of compound of Formula 1
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를Purified water 가하여 전체 900 By adding a full 900 mLmL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L-용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용하였다.After mixing the above components according to the conventional healthy beverage production method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained by sterilization in a sterilized 2L-container, sealed sterilization and then stored in the refrigerator It was used to prepare a healthy beverage composition of the invention.
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
2. 야채주스의 제조2. Preparation of Vegetable Juice
본 발명의 화학식 1의 화합물 1g을 토마토 또는 당근 주스 1,000mL에 가하여 건강 증진용 야채주스를 제조하였다.
1 g of the compound of Chemical Formula 1 of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.
3. 과일주스의 제조3. Preparation of Fruit Juice
화학식 1의 화합물 1 g을 사과 또는 포도 주스 1,000 mL에 가하여 건강 증진용 과일주스를 제조하였다.
1 g of the compound of Formula 1 was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.
Claims (20)
[화학식 1]
A pharmaceutical composition for improving skin wrinkles comprising the compound represented by Formula 1 as an active ingredient:
[Formula 1]
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 조성물.
The method of claim 1,
A composition comprising 0.0001 to 10% by weight of the active ingredient relative to the total composition.
[화학식 1]
Skin external preparation for improving skin wrinkles comprising a compound represented by the following formula 1 as an active ingredient:
[Formula 1]
외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 피부 외용제.
The method of claim 3, wherein
The external preparation is an external preparation for skin in the form of an ointment, patch, gel, cream or spray.
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 피부 외용제.
The method of claim 3, wherein
Skin external preparation containing the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
A cosmetic composition for improving skin wrinkles comprising the compound represented by Formula 1 as an active ingredient:
[Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 화장료 조성물.
The method according to claim 6,
Cosmetic composition in the form of a lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 화장료 조성물.
The method according to claim 6,
Cosmetic composition comprising the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
A health food for improving skin wrinkles comprising a compound represented by the following Formula 1 as an active ingredient:
[Formula 1]
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 건강 식품.
The method of claim 9,
Health food comprising the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
A whitening pharmaceutical composition comprising the compound represented by Chemical Formula 1 as an active ingredient:
[Formula 1]
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 조성물.
The method of claim 11,
A composition comprising 0.0001 to 10% by weight of the active ingredient relative to the total composition.
[화학식 1]
Whitening skin external preparation using the compound represented by the following Chemical Formula 1 as an active ingredient:
[Formula 1]
외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 피부 외용제.
The method of claim 13,
The external preparation is an external preparation for skin in the form of an ointment, patch, gel, cream or spray.
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 피부 외용제.
The method of claim 13,
Skin external preparation containing the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
A cosmetic composition for whitening comprising a compound represented by the formula (1) as an active ingredient:
[Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 화장료 조성물.
17. The method of claim 16,
Cosmetic composition in the form of a lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 화장료 조성물.
17. The method of claim 16,
Cosmetic composition comprising the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
[화학식 1]
Health food for whitening comprising a compound represented by the formula (1) as an active ingredient:
[Formula 1]
상기 유효성분을 전체 조성물 대비 0.0001 내지 10 중량%로 포함하는 건강 식품.The method of claim 19,
Health food comprising the active ingredient in an amount of 0.0001 to 10% by weight relative to the total composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120004449 | 2012-01-13 | ||
KR20120004449 | 2012-01-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130083798A true KR20130083798A (en) | 2013-07-23 |
KR101904916B1 KR101904916B1 (en) | 2018-10-08 |
Family
ID=48994700
Family Applications (38)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120039946A KR101832286B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039951A KR101872916B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039940A KR101832283B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039943A KR101890322B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039949A KR101637375B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039942A KR101832285B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039948A KR101809753B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039947A KR101792028B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039941A KR101832284B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039950A KR20130083778A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039945A KR101792031B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039944A KR20130083772A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041758A KR101872917B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041766A KR101809754B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041761A KR101815000B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041767A KR101841256B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041768A KR101909235B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041765A KR101814999B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041760A KR101850711B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041757A KR101855094B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041756A KR101841255B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041770A KR101792029B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041769A KR101851625B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041759A KR101872918B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047641A KR101931977B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120047635A KR20130083793A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047639A KR101853902B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047637A KR20130083795A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047642A KR101839484B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120047640A KR101904916B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120047636A KR101909236B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047638A KR101904917B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120048928A KR101847013B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
KR1020120048926A KR20130083804A (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048923A KR101931978B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048924A KR101855095B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048927A KR101909237B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
KR1020120048925A KR101847012B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
Family Applications Before (29)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120039946A KR101832286B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039951A KR101872916B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039940A KR101832283B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039943A KR101890322B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039949A KR101637375B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039942A KR101832285B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039948A KR101809753B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039947A KR101792028B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039941A KR101832284B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039950A KR20130083778A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039945A KR101792031B1 (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120039944A KR20130083772A (en) | 2012-01-13 | 2012-04-17 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041758A KR101872917B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041766A KR101809754B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041761A KR101815000B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041767A KR101841256B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041768A KR101909235B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041765A KR101814999B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041760A KR101850711B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041757A KR101855094B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041756A KR101841255B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041770A KR101792029B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041769A KR101851625B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120041759A KR101872918B1 (en) | 2012-01-13 | 2012-04-20 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047641A KR101931977B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120047635A KR20130083793A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047639A KR101853902B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047637A KR20130083795A (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047642A KR101839484B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120047636A KR101909236B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and enhancing elasticity |
KR1020120047638A KR101904917B1 (en) | 2012-01-13 | 2012-05-04 | Composition for improving skin wrinkle and whitening |
KR1020120048928A KR101847013B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
KR1020120048926A KR20130083804A (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048923A KR101931978B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048924A KR101855095B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
KR1020120048927A KR101909237B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing elasticity and whitening |
KR1020120048925A KR101847012B1 (en) | 2012-01-13 | 2012-05-09 | Composition for enhancing whitening |
Country Status (1)
Country | Link |
---|---|
KR (38) | KR101832286B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150049401A (en) | 2013-10-30 | 2015-05-08 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising Monotropein |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101453190B1 (en) * | 2013-01-17 | 2014-10-22 | 주식회사 엘지생활건강 | Composition for improving skin wrinkle containing amarogentin |
FR3010307B1 (en) * | 2013-09-12 | 2017-05-05 | Basf Beauty Care Solutions France Sas | COSMETIC OR DERMATOLOGICAL USE OF AVICULARIN |
CN103520092B (en) * | 2013-10-29 | 2015-10-28 | 浙江中医药大学 | Monocrotaline gel and preparation method thereof |
KR102040157B1 (en) * | 2013-10-30 | 2019-11-04 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising linderalactone |
KR20150049417A (en) * | 2013-10-30 | 2015-05-08 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation and skin whitening comprising Harpagoside |
KR101909739B1 (en) | 2013-10-30 | 2018-10-18 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-inflammation and skin whitening comprising Harpagide |
KR20150057899A (en) * | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation or skin whitening |
KR102013128B1 (en) * | 2013-11-20 | 2019-08-22 | 주식회사 엘지생활건강 | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient |
US9914289B2 (en) | 2014-01-08 | 2018-03-13 | Lg Chem, Ltd. | System for laminating optical film and method for manufacturing display unit using the same |
KR102142492B1 (en) * | 2014-08-13 | 2020-08-07 | 주식회사 엘지생활건강 | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, skin moisturizing or anti-inflammation comprising aurantio-obtusin or a pharmaceutically acceptable salt thereof |
KR102224110B1 (en) * | 2014-10-15 | 2021-03-09 | (주)아모레퍼시픽 | Composition for reducing the skin pore containing a substance related to regulation of ABH antigen expression |
KR102199884B1 (en) * | 2014-10-15 | 2021-01-08 | (주)아모레퍼시픽 | Composition for controlling sebum containing a substance related to regulation of ABH antigen expression |
CN104288167B (en) * | 2014-10-29 | 2017-08-25 | 马应龙药业集团股份有限公司 | It is a kind of to treat otoginsenoside preparation of sodium of hemorrhoid and preparation method thereof |
KR102553374B1 (en) | 2016-06-14 | 2023-07-06 | 주식회사 엘지생활건강 | Composition for prevention or treatment of dental disease comprising cistanoside A |
CN106176606B (en) * | 2016-08-08 | 2019-01-01 | 武汉爱民制药股份有限公司 | sodium aescinate aerosol |
CN107759656A (en) * | 2016-08-22 | 2018-03-06 | 黑龙江迪龙制药有限公司 | A kind of preparation method of Sodium Aescinate |
KR20180058411A (en) * | 2016-11-24 | 2018-06-01 | 대한민국(환경부 국립생물자원관장) | Cosmetic composition for antioxidant comprising Alnus firma extract as active ingredients |
KR101907850B1 (en) * | 2017-04-07 | 2018-10-15 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturing comprising Protaetia brevitarsis extract or compound isolated therefrom as effective component |
KR102053994B1 (en) * | 2017-12-22 | 2019-12-10 | 재단법인 전주농생명소재연구원 | Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component |
CN110314122B (en) * | 2018-03-30 | 2023-04-07 | 广州箴美科技有限公司 | Alisma extract and preparation method and application thereof |
KR102633917B1 (en) * | 2019-05-30 | 2024-02-06 | (주)아모레퍼시픽 | Composition for reinforcing skin elasticity |
CN111534483B (en) * | 2020-05-23 | 2020-12-18 | 广东壹加再生医学研究院有限公司 | Application of insulin-like growth factor binding protein 7 activator in chondrogenic differentiation of human umbilical cord mesenchymal stem cells |
CN111529426A (en) * | 2020-06-13 | 2020-08-14 | 南京奥赛斯生物科技有限公司 | Application of plant small molecules in improving skin elasticity and preparing beauty skin care products |
KR102431445B1 (en) * | 2020-09-21 | 2022-08-11 | 주식회사 서미바이오 | Method for manufacturing cream-type cosmetic product containing grub powder |
TWI845870B (en) * | 2020-10-27 | 2024-06-21 | 大江生醫股份有限公司 | Use of peony flower extract for improving skin condition |
KR102611368B1 (en) * | 2020-12-03 | 2023-12-06 | 제주대학교 산학협력단 | A composition for promoting melanin synthesis comprising didymin |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050092313A (en) * | 2004-03-15 | 2005-09-21 | 주식회사 엘지생활건강 | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS617216A (en) * | 1984-06-21 | 1986-01-13 | Shiseido Co Ltd | External remedy for skin |
JP3135294B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
JP3135292B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
JP3135293B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
JP2829157B2 (en) * | 1991-07-10 | 1998-11-25 | 株式会社資生堂 | External preparation for skin |
JPH0517336A (en) * | 1991-07-10 | 1993-01-26 | Shiseido Co Ltd | Skin medicine for external use |
JP3135295B2 (en) * | 1991-07-10 | 2001-02-13 | 株式会社資生堂 | External preparation for skin |
JP3443130B2 (en) * | 1992-03-19 | 2003-09-02 | 株式会社資生堂 | External preparation for skin |
JP3251635B2 (en) * | 1992-03-19 | 2002-01-28 | 株式会社資生堂 | External preparation for skin |
FR2695561B1 (en) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care. |
US5529769A (en) | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
JPH0940523A (en) | 1995-07-28 | 1997-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoter containing water extract form chlorella |
JPH0967388A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Production of saikosaponin |
JPH0977632A (en) * | 1995-09-14 | 1997-03-25 | Shiseido Co Ltd | Dermal preparation for external use |
JP3966922B2 (en) | 1996-07-18 | 2007-08-29 | 一丸ファルコス株式会社 | Fibroblast growth promoter |
KR100358937B1 (en) | 1998-04-23 | 2003-03-17 | 주식회사 엘지생명과학 | Water-soluble extract of anemarrhena asphodeloides bunge having growth hormone release stimulating activity and growth hormone release stimulating factor separated therefrom |
JP2001039850A (en) * | 1999-07-27 | 2001-02-13 | Shiseido Co Ltd | Agent for accelerating shrinkage of collagen gel |
JP2001352938A (en) * | 2000-06-16 | 2001-12-25 | Rasheru Seiyaku Kk | Health food |
JP2002187816A (en) * | 2000-10-10 | 2002-07-05 | Noevir Co Ltd | Bleaching cosmetic |
KR20020044855A (en) * | 2000-12-07 | 2002-06-19 | 성재갑 | Oral compositions containing xanthorrhizol as an inhibitor of reactive oxygen species and nitric oxide for dental hygiene |
US6589514B2 (en) | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
CA2473874C (en) * | 2001-12-14 | 2011-11-22 | Council Of Scientific And Industrial Research | A composition for treating neurocerebrovascular disorders |
CN100471490C (en) * | 2002-08-01 | 2009-03-25 | 谢恬 | Sesquiterpene ketone injection, preparing method and use thereof |
US20040161435A1 (en) * | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
JP4256389B2 (en) * | 2003-11-17 | 2009-04-22 | セダーマ | Composition comprising a mixture of tetrapeptide and tripeptide |
KR20050082447A (en) * | 2004-02-19 | 2005-08-24 | 주식회사 엠디바이오알파 | Diabete treatment with tetrahydroberberine |
JP2005281284A (en) * | 2004-03-26 | 2005-10-13 | Ivy Cosmetics Corp | Skin care preparation for external use for promoting collagen synthesis |
MXPA06013250A (en) | 2004-05-14 | 2007-02-28 | Abbott Lab | Kinase inhibitors as therapeutic agents. |
US20050271608A1 (en) | 2004-06-05 | 2005-12-08 | Gupta Shyam K | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives |
US20070166255A1 (en) * | 2004-11-22 | 2007-07-19 | Gupta Shyam K | Treatment of Topical Discomforts Including Acne, Sunburn, Diaper Rash, Wound, Wrinkles and Dandruff/Hair Loss by Natural Lignans via Fatty Acid Desaturase Inhibition |
CN1676165A (en) | 2004-12-29 | 2005-10-05 | 山东蓝金生物工程有限公司 | In vivo slow-releasing anticancer medicinal composition |
CN1872083B (en) | 2005-05-31 | 2010-07-21 | 山东绿叶天然药物研究开发有限公司 | Application of monarda glycoside in preparing medicine for treating or preventing hemorrhagic disease |
JP4861753B2 (en) * | 2006-06-20 | 2012-01-25 | 花王株式会社 | Skin external composition |
EP2187762B1 (en) * | 2007-09-11 | 2015-01-21 | DSM IP Assets B.V. | Use of sesquiterpenes as feed additives in animal feed |
CN101474274B (en) | 2008-12-24 | 2012-06-27 | 贵州信邦制药股份有限公司 | Quality control method of Shensu Chinese medicine preparation |
DE102009002227A1 (en) | 2009-04-06 | 2010-10-07 | Henkel Ag & Co. Kgaa | Skin treatment against skin aging I |
KR101100678B1 (en) * | 2009-06-04 | 2012-01-03 | 웅진코웨이주식회사 | Cosmetic Composition comprising plant extracts |
CN102107006A (en) | 2009-12-25 | 2011-06-29 | 奇复康药物研发(苏州)有限公司 | Coupling medicament for treating diabetes mellitus and medicinal application thereof |
JP2012001467A (en) * | 2010-06-15 | 2012-01-05 | Naris Cosmetics Co Ltd | Skin external preparation |
-
2012
- 2012-04-17 KR KR1020120039946A patent/KR101832286B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039951A patent/KR101872916B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039940A patent/KR101832283B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039943A patent/KR101890322B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039949A patent/KR101637375B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039942A patent/KR101832285B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039948A patent/KR101809753B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039947A patent/KR101792028B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039941A patent/KR101832284B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039950A patent/KR20130083778A/en not_active Application Discontinuation
- 2012-04-17 KR KR1020120039945A patent/KR101792031B1/en active IP Right Grant
- 2012-04-17 KR KR1020120039944A patent/KR20130083772A/en not_active Application Discontinuation
- 2012-04-20 KR KR1020120041758A patent/KR101872917B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041766A patent/KR101809754B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041761A patent/KR101815000B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041767A patent/KR101841256B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041768A patent/KR101909235B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041765A patent/KR101814999B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041760A patent/KR101850711B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041757A patent/KR101855094B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041756A patent/KR101841255B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041770A patent/KR101792029B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041769A patent/KR101851625B1/en active IP Right Grant
- 2012-04-20 KR KR1020120041759A patent/KR101872918B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047641A patent/KR101931977B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047635A patent/KR20130083793A/en not_active Application Discontinuation
- 2012-05-04 KR KR1020120047639A patent/KR101853902B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047637A patent/KR20130083795A/en not_active Application Discontinuation
- 2012-05-04 KR KR1020120047642A patent/KR101839484B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047640A patent/KR101904916B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047636A patent/KR101909236B1/en active IP Right Grant
- 2012-05-04 KR KR1020120047638A patent/KR101904917B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048928A patent/KR101847013B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048926A patent/KR20130083804A/en not_active Application Discontinuation
- 2012-05-09 KR KR1020120048923A patent/KR101931978B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048924A patent/KR101855095B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048927A patent/KR101909237B1/en active IP Right Grant
- 2012-05-09 KR KR1020120048925A patent/KR101847012B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050092313A (en) * | 2004-03-15 | 2005-09-21 | 주식회사 엘지생활건강 | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation |
Non-Patent Citations (6)
Title |
---|
J Med Food 8 (4) 2005, 552?555 * |
경희대학교 의과대학원 석사학위 논문, 2007 * |
비특허문헌 1 (경희대학교 의학대학원, 석사학위논문, 2007) * |
비특허문헌 2 (Z. NATURFORSCH., 2007) * |
비특허문헌 3 (BIOL. PHARM. BULL., 2005) * |
비특허문헌 4 (J. MED. FOOD, 2005) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150049401A (en) | 2013-10-30 | 2015-05-08 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising Monotropein |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101904916B1 (en) | Composition for improving skin wrinkle and whitening | |
KR102201193B1 (en) | Composition for skin cell regeneration, anti-wrinkle, anti-inflammation, or skin whitening | |
KR102013163B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and skin whitening | |
KR102001048B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
KR102048879B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102014396B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102040157B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising linderalactone | |
KR20190135444A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20190096882A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20190094325A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |